Navigation Links
EVT in Medical News

Evotec Reports Positive Top-Line Results in Phase II Study With EVT 201 in Elderly Insomniacs With Daytime Sleepiness

Statistical Significance in Primary and Key Secondary Endpoints at Both Doses Data Confirm Robust Sleep Onset and Sleep Maintenance Effects Seen in the First Phase II Study in the Adult Population HAMBURG, Germany and OXFORD, England, October 16 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt...

Alzheimer’s disease trial With EVT 101 For Successfully Complete

Alzheimer’s disease is a dreaded disease for the elderly. In the direction of its treatment , the effort of Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30, "Evotec") has successfully completed the single ascending dose component // of the Phase I clinical study with EVT 101, a subtype-specific...
EVT in Medical Technology

Evotec's EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity During the Performance of Cognitive Tasks

Single-Dose, Volunteer fMRI Study Completed and Reported Today Dosing in Four Week Higher Repeat Dose Study Completed HAMBURG, Germany and OXFORD, England, March 28 /PRNewswire-FirstCall/ -- Evotec (Frankfurt Stock Exchange: EVT) is pleased to announce the preliminary findings of ...

Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201

Both Co-Primary Endpoints, Wake After Sleep Onset and Total Sleep Time, and Key Secondary Endpoints, Including Latency to Persistent Sleep, Were Met at Both Doses HAMBURG, Germany and OXFORD, England, June 04, 2007 /PRNewswire-FirstCall/ -- Evotec AG announced today positive top-line results from ...

Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...

... results from its first phase II clinical trial of evt 201 in patients with chronic primary insomnia. evt 201 is a partial positive allosteric modulator (pP...controlled cross-over study design of two doses of evt 201 (1.5mg and 2.5mg) in 67 patients was conducted...
EVT in Biological Technology

Evotec Starts Phase II in Smoking Cessation with EVT 302

HAMBURG, Germany and OXFORD, England, February 28 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) today announced the start of its first Phase II study for EVT 302 in smoking cessation, a reversible and highly selective inhibitor of monoamine oxidase B (MAO-B). This doubl...

Phase I Safety and Tolerability Study With EVT 302 Successfully Completed

HAMBURG, Germany and OXFORD, England, January 7 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) today announced that it has successfully completed a Phase I safety and tolerability study with EVT 302. The preliminary results confirm the good tolerability profile of EVT 302 ...

Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201

Very Robust Findings on the Key Problems Faced by Insomniacs, i.e. Sleep Onset and Sleep Maintenance Evotec to Host a Conference Call Today at 11:00 am CET (10:00 am UK time, 5:00 am EST, 7:00 pm AEST) Directly From the Worldsleep07 Congress in Australia HAMBURG, Germany and OXFORD, England,...

Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia

HAMBURG, Germany and OXFORD, England, August 28 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) is pleased to invite you to a webcast presentation and conference call on detailed Phase II data for its lead compound EVT 201 in the treatment of insomnia on 5 September 2007 at...

Evotec Announces Financial Results for 2007

... Positive data from two Phase II trials evaluating evt 201 strengthening confidence in evt 201's potential advantages over competitive insomnia therapies - Phase I safety data for evt 302 revealed good tolerance up to the highest d...

Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis

...logies acquired ("In-process Research and Development") in the amount of EUR 38.5 million, in particular to Evotec's clinical programs EVT 201 and the evt 100 series, which according to IFRS has to be capitalized and to be carried forward according to IAS 38. EUR 7.1 million was allocated to the customer...

Evotec Reports Third Quarter 2007 Results

... Phase II trials with lead insomnia drug candidate evt 201 - Sale of the Chemical Development Business t... two Phase II studies with insomnia drug candidate evt 201 - In adult insomniacs (first study), evt 201 showed highly statistically significant effect...

Evotec AG: R&D Update on 16 October 2007 Live on the Internet

...entral Nervous System. Evotec has three programmes in clinical development: evt 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor c...ceptor antagonist for the treatment of Alzheimer's disease and/or pain, and evt 302, a MAO-B inhibitor in development for smoking cessation. On 19 Septemb...

Evotec to Present at the UBS 2007 Global Life Sciences Conference in New York

...entral Nervous System. Evotec has three programmes in clinical development: evt 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor c...ceptor antagonist for the treatment of Alzheimer's disease and/or pain, and evt 302, a MAO-B inhibitor in development for smoking cessation. http://www.e...
Other Tags
(Date:4/1/2015)... (PRWEB) April 01, 2015 Nike Golf ... Development Camps in Arizona and Florida. These programs are ... lower their score in a golf-intensive environment and to ... led by University of Arizona coaching legend, Rick LaRose, ... on the knowledge gaps as it pertains to the ...
(Date:4/1/2015)... IL (PRWEB) April 01, 2015 Poisonous ... greatly from climate change in recent years, increasing significantly ... an allergic reaction if exposed to poison plants (according ... enthusiasts and families prepare for summer adventures in nature, ... uncomfortable poison plant reaction is greater than ever. This ...
(Date:3/31/2015)... Los Angeles, California (PRWEB) March 31, 2015 ... Caregiver Services has started to hire more caregivers, ... public relations personnel and care managers within the ... expansion the company's training institution, 1Heart Caregiver University ... to assist with its mission to provide quality ...
(Date:3/31/2015)... April 01, 2015 Every day a ... (standard American diet) contains things banned in other countries, ... rockets every year. AlignLife Chiropractic & Natural Health Centers ... also their communities they can reduce the future development ... year each AlignLife clinic offers workshops at no charge ...
(Date:3/31/2015)... As the demand for optimized mobile ... have a mobile-friendly website online sometime during the month ... Fitness’ continued commitment to bring the best and most ... of the same great fitness information at http://www.chunkfitness.com ... easier to read while browsing on a mobile device. ...
Breaking Medicine News(10 mins):Health News:US Sports Camps and Nike Golf Camps to Host Golf Development Camps in Arizona and Florida 2Health News:US Sports Camps and Nike Golf Camps to Host Golf Development Camps in Arizona and Florida 3Health News:New Ivarest Poison Ivy Itch Spray Provides All-Day Comfort 2Health News:1Heart Ends 1st Quarter of the Year With 1Heart Caregiver University Training of New Staff and Commits To Provide More Jobs For Year 2015 2Health News:1Heart Ends 1st Quarter of the Year With 1Heart Caregiver University Training of New Staff and Commits To Provide More Jobs For Year 2015 3
(Date:3/10/2015)... , March 10, 2015  Continuing its 167-year ... Unexpected, Hammacher Schlemmer introduces The Eye Scanning Password ... before granting access to secure websites or sensitive data. ... verify travelers at international borders, the device has a ... pattern points of the iris, converting them into an ...
(Date:3/10/2015)...   Tute Genomics , pioneer in affordable, accurate ... sequencing company PrimBio Research Institute to be ... panel interpretation. PrimBio, a certified Life Technologies ... technologies to support the work of experts on the ... types of exome sequencing services: 1) Targeted Exome and ...
(Date:3/5/2015)... In Brazil , cloud computing ... these solutions and 42 percent planning to invest in them ... percent of the companies will be investing in these solutions ... companies in the region are currently opting for the private ... command significant attention in the coming years. This trend is ...
Breaking Biology News(10 mins):Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4
Other Contents